stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. KURA
    stockgist
    HomeTop MoversCompaniesConcepts
    KURA logo

    Kura Oncology, Inc.

    KURA
    NASDAQ
    Healthcare
    Biotechnology
    San Diego, CA, US192 employeeskuraoncology.com
    $8.71
    +0.10(1.2%)

    52W $5.54 – $12.14

    AI-generated from 10-K FY2025 filed Mar 4, 2026

    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

    Revenue breakdown: License And Collaboration Revenue (49.1%), Collaboration Revenue (49.1%), Product (1.8%).

    $769MMkt Cap
    $68MRev TTM
    -$280MNI TTM
    -2.6xP/E TTM

    Latest Earnings

    10-K
    FY FY2025Mar 4, 2026

    10-K for FY2025 was filed on 2026-03-05. AI summary is not available yet.

    Read full analysisView SEC Filing

    What Changed Recently

    Financial ResultsMar 4, 2026

    and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

    View filing →
    Charter AmendmentJan 28, 2026

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 28, 2026, the board of directors (the “Board”) of Kura Oncology, Inc. (the

    View filing →
    Financial ResultsJan 11, 2026

    and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

    View filing →
    View all recent events →
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Mix3
    License And Collaboration Revenue49.1%($119M)
    Collaboration Revenue49.1%($119M)
    Product1.8%($4M)

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    TNGX logo
    TNGXTango Therapeutics, Inc.
    $21.42-0.97%$2.5B-21.7
    TYRA logo
    TYRATyra Biosciences, Inc.
    $39.92+0.78%$2.1B-18.1
    BCAX logo
    BCAXBicara Therapeutics Inc. ...
    $21.45-0.09%$1.2B-8.3
    SVRA logo
    SVRASavara Inc.
    $5.66+1.85%$1.2B-9.5
    EYPT logo
    EYPTEyePoint Pharmaceuticals,...
    $12.87-3.96%$1.1B-4.6
    MRVI logo
    MRVIMaravai LifeSciences Hold...
    $2.98+1.19%$820M-3.4
    REPL logo
    REPLReplimune Group, Inc.
    $8.83+4.99%$729M-2.0
    PRME logo
    PRMEPrime Medicine, Inc.
    $3.44+3.73%$622M-2.6
    Company Profile
    CIK0001422143
    ISINUS50127T1097
    CUSIP50127T109
    Phone858 500 8800
    Address12730 High Bluff Drive, San Diego, CA, 92130, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice